Symbols / QNRX $7.02 +15.84% Quoin Pharmaceuticals, Ltd.
QNRX Chart
About
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.66M |
| Enterprise Value | 351.72M | Income | -15.80M | Sales | — |
| Book/sh | 8.76 | Cash/sh | 0.36 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -2.23 | PEG | — |
| P/S | — | P/B | 0.80 | P/C | — |
| EV/EBITDA | -21.72 | EV/Sales | — | Quick Ratio | 3.38 |
| Current Ratio | 3.61 | Debt/Eq | 17.71 | LT Debt/Eq | — |
| EPS (ttm) | -518.00 | EPS next Y | -3.15 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 09:00 | ROA | -56.41% |
| ROE | -141.59% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.80M |
| Shs Float | 41.16M | Short Float | 0.48% | Short Ratio | 0.28 |
| Short Interest | — | 52W High | 41.80 | 52W Low | 5.01 |
| Beta | 1.82 | Avg Volume | 102.56K | Volume | 59.52K |
| Target Price | $29.67 | Recom | Strong_buy | Prev Close | $6.06 |
| Price | $7.02 | Change | 15.84% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$29.67
Mean price target
2. Current target
$6.80
Latest analyst target
3. DCF / Fair value
$29.67
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$6.80
Low
$14.00
High
$40.00
Mean
$29.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-03-15 | main | Maxim Group | Buy → Buy | $4 |
- FDA Fast Tracks lotion for rare genetic skin disorder with no approved treatment - Stock Titan Wed, 11 Mar 2026 07
- $QNRX stock is up 14% today. Here's what we see in our data. - quiverquant.com Wed, 17 Dec 2025 08
- Market Sentiment Around Loss-Making Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) - simplywall.st hu, 26 Mar 2026 07
- Price-Driven Insight from (QNRX) for Rule-Based Strategy - Stock Traders Daily hu, 26 Mar 2026 17
- Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com Fri, 10 Oct 2025 07
- Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On? - Benzinga Fri, 10 Oct 2025 07
- Financing Covenants Put Quoin Pharmaceuticals at Heightened Risk of Funding Shortfall and Program Delays - theglobeandmail.com Sun, 29 Mar 2026 06
- QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally? - Stocktwits ue, 11 Nov 2025 15
- Quoin Pharma sets March 26 update with 2025 results before market open - Stock Titan hu, 19 Mar 2026 07
- QNRX Stock Soars 300% After $104.5M Financing Through Private Placement - Stocktwits Fri, 10 Oct 2025 07
- Stonepine Capital (QNRX) files Form 4 as 10% owner with no trades - Stock Titan ue, 31 Mar 2026 17
- Quoin lands $104.5M as rare skin drug child study expands - Stock Titan hu, 26 Mar 2026 12
- FDA opens door to a single late-stage trial for Quoin skin drug - Stock Titan Wed, 25 Mar 2026 07
- If You Invested $1,000 in Quoin Pharmaceuticals Ltd (QNRX) - Stock Titan Mon, 23 Mar 2026 03
- Quoin (NASDAQ: QNRX) to make clinical/stability batches after 4% and 5% rapamycin loads - Stock Titan ue, 11 Nov 2025 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
16.29
+70.97%
|
9.53
+1.60%
|
9.38
+1.30%
|
9.26
|
| Research And Development |
|
9.80
+172.10%
|
3.60
+8.91%
|
3.31
+23.76%
|
2.67
|
| Selling General And Administration |
|
6.49
+9.49%
|
5.93
-2.38%
|
6.07
-7.81%
|
6.58
|
| General And Administrative Expense |
|
6.49
+9.49%
|
5.93
-2.38%
|
6.07
-7.81%
|
6.58
|
| Other Gand A |
|
6.49
+9.49%
|
5.93
-2.38%
|
6.07
-7.81%
|
6.58
|
| Total Expenses |
|
16.29
+70.97%
|
9.53
+1.60%
|
9.38
+1.30%
|
9.26
|
| Operating Income |
|
-16.29
-70.97%
|
-9.53
-1.60%
|
-9.38
-1.30%
|
-9.26
|
| EBITDA |
|
-16.19
-71.72%
|
-9.43
-1.66%
|
-9.27
-8.31%
|
-8.56
|
| Normalized EBITDA |
|
-16.19
-71.63%
|
-9.44
-1.77%
|
-9.27
-3.25%
|
-8.98
|
| Reconciled Depreciation |
|
0.10
+0.00%
|
0.10
-3.57%
|
0.10
-0.32%
|
0.10
|
| EBIT |
|
-16.29
-70.97%
|
-9.53
-1.60%
|
-9.38
-8.20%
|
-8.67
|
| Total Unusual Items |
|
0.00
-46.95%
|
0.01
+379.61%
|
-0.00
-100.64%
|
0.42
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-46.95%
|
0.01
+379.61%
|
-0.00
-100.64%
|
0.42
|
| Special Income Charges |
|
—
|
—
|
0.00
-100.00%
|
0.42
|
| Other Special Charges |
|
—
|
—
|
—
|
-0.42
|
| Net Income |
|
-15.80
-76.34%
|
-8.96
-3.18%
|
-8.69
+7.41%
|
-9.38
|
| Pretax Income |
|
-15.80
-76.34%
|
-8.96
-3.18%
|
-8.69
+7.41%
|
-9.38
|
| Net Non Operating Interest Income Expense |
|
0.48
-13.68%
|
0.56
-19.60%
|
0.69
+212.34%
|
-0.62
|
| Interest Expense Non Operating |
|
—
|
—
|
0.00
-100.00%
|
0.71
|
| Net Interest Income |
|
0.48
-13.68%
|
0.56
-19.60%
|
0.69
+212.34%
|
-0.62
|
| Interest Expense |
|
—
|
—
|
0.00
-100.00%
|
0.71
|
| Interest Income Non Operating |
|
0.48
-13.68%
|
0.56
-19.60%
|
0.69
+625.48%
|
0.10
|
| Interest Income |
|
0.48
-13.68%
|
0.56
-19.60%
|
0.69
+625.48%
|
0.10
|
| Other Income Expense |
|
0.00
-46.95%
|
0.01
+379.61%
|
-0.00
-100.54%
|
0.49
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
0.08
|
| Gain On Sale Of Security |
|
0.00
-46.95%
|
0.01
+379.61%
|
-0.00
-305.28%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-15.80
-76.34%
|
-8.96
-3.18%
|
-8.69
+7.41%
|
-9.38
|
| Net Income From Continuing Operation Net Minority Interest |
|
-15.80
-76.34%
|
-8.96
-3.18%
|
-8.69
+7.41%
|
-9.38
|
| Net Income From Continuing And Discontinued Operation |
|
-15.80
-76.34%
|
-8.96
-3.18%
|
-8.69
+7.41%
|
-9.38
|
| Net Income Continuous Operations |
|
-15.80
-76.34%
|
-8.96
-3.18%
|
-8.69
+7.41%
|
-9.38
|
| Normalized Income |
|
-15.81
-76.24%
|
-8.97
-3.29%
|
-8.68
+11.38%
|
-9.80
|
| Net Income Common Stockholders |
|
-15.80
-76.34%
|
-8.96
-3.18%
|
-8.69
+8.05%
|
-9.45
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
0.00
-100.00%
|
0.07
|
| Diluted EPS |
|
—
|
-66.85
+80.19%
|
-337.47
+79.40%
|
-1,638.23
|
| Basic EPS |
|
—
|
-66.85
+80.19%
|
-337.47
+79.40%
|
-1,638.23
|
| Basic Average Shares |
|
—
|
0.13
+420.43%
|
0.03
+346.43%
|
0.01
|
| Diluted Average Shares |
|
—
|
0.13
+420.43%
|
0.03
+346.43%
|
0.01
|
| Diluted NI Availto Com Stockholders |
|
-15.80
-76.34%
|
-8.96
-3.18%
|
-8.69
+8.05%
|
-9.45
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Assets |
|
12.17
-15.83%
|
14.46
|
—
|
| Current Assets |
|
11.29
-15.59%
|
13.37
|
—
|
| Cash Cash Equivalents And Short Term Investments |
|
10.69
-16.79%
|
12.85
|
—
|
| Cash And Cash Equivalents |
|
2.40
-16.06%
|
2.86
|
—
|
| Cash Financial |
|
—
|
2.86
-61.77%
|
7.48
|
| Other Short Term Investments |
|
8.29
-17.00%
|
9.99
|
—
|
| Prepaid Assets |
|
0.56
+8.10%
|
0.52
|
—
|
| Current Deferred Assets |
|
0.03
|
0.00
|
0.00
|
| Total Non Current Assets |
|
0.88
-18.81%
|
1.09
|
—
|
| Goodwill And Other Intangible Assets |
|
0.58
-17.21%
|
0.70
|
—
|
| Other Intangible Assets |
|
0.58
-17.21%
|
0.70
|
—
|
| Non Current Prepaid Assets |
|
0.30
-21.75%
|
0.38
|
—
|
| Other Non Current Assets |
|
—
|
—
|
0.05
|
| Total Liabilities Net Minority Interest |
|
6.51
-7.74%
|
7.05
|
—
|
| Current Liabilities |
|
3.58
+1.53%
|
3.53
|
—
|
| Payables And Accrued Expenses |
|
3.58
+1.53%
|
3.53
|
—
|
| Payables |
|
1.22
-10.60%
|
1.37
|
—
|
| Accounts Payable |
|
0.53
-13.06%
|
0.61
|
—
|
| Current Accrued Expenses |
|
2.36
+9.18%
|
2.16
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
—
|
| Total Tax Payable |
|
0.09
-41.11%
|
0.16
|
—
|
| Other Current Liabilities |
|
—
|
—
|
0.37
|
| Total Non Current Liabilities Net Minority Interest |
|
2.92
-17.03%
|
3.52
|
—
|
| Tradeand Other Payables Non Current |
|
0.00
|
0.00
|
—
|
| Stockholders Equity |
|
5.66
-23.53%
|
7.41
|
—
|
| Common Stock Equity |
|
5.66
-23.53%
|
7.41
|
—
|
| Capital Stock |
|
0.00
|
0.00
|
—
|
| Common Stock |
|
0.00
|
0.00
|
—
|
| Share Issued |
|
0.99
+144.43%
|
0.40
|
—
|
| Ordinary Shares Number |
|
0.99
+144.46%
|
0.40
|
—
|
| Treasury Shares Number |
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Additional Paid In Capital |
|
51.87
+8.38%
|
47.86
|
—
|
| Retained Earnings |
|
-46.20
-23.15%
|
-37.52
|
—
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
—
|
| Treasury Stock |
|
0.00
-100.00%
|
2.93
+0.00%
|
2.93
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
5.66
-23.53%
|
7.41
|
—
|
| Total Capitalization |
|
5.66
-23.53%
|
7.41
|
—
|
| Working Capital |
|
7.70
-21.72%
|
9.84
|
—
|
| Invested Capital |
|
5.66
-23.53%
|
7.41
|
—
|
| Net Tangible Assets |
|
5.08
-24.19%
|
6.70
|
—
|
| Tangible Book Value |
|
5.08
-24.19%
|
6.70
|
—
|
| Dueto Related Parties Current |
|
0.60
+0.00%
|
0.60
|
—
|
| Dueto Related Parties Non Current |
|
2.92
-17.03%
|
3.52
|
—
|
| Interest Payable |
|
1.15
+0.00%
|
1.15
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-13.54
-72.34%
|
-7.86
+0.09%
|
-7.86
+7.27%
|
-8.48
|
| Cash Flow From Continuing Operating Activities |
|
-13.54
-72.34%
|
-7.86
+0.09%
|
-7.86
+7.27%
|
-8.48
|
| Net Income From Continuing Operations |
|
-15.80
-76.34%
|
-8.96
-3.18%
|
-8.69
+7.41%
|
-9.38
|
| Depreciation Amortization Depletion |
|
0.10
+0.00%
|
0.10
-3.57%
|
0.10
-0.32%
|
0.10
|
| Amortization Cash Flow |
|
0.10
+0.00%
|
0.10
-3.57%
|
0.10
-0.32%
|
0.10
|
| Depreciation And Amortization |
|
0.10
+0.00%
|
0.10
-3.57%
|
0.10
-0.32%
|
0.10
|
| Amortization Of Intangibles |
|
0.10
+0.00%
|
0.10
-3.57%
|
0.10
-0.32%
|
0.10
|
| Other Non Cash Items |
|
—
|
—
|
—
|
0.71
|
| Stock Based Compensation |
|
1.15
-8.87%
|
1.26
+15.01%
|
1.09
+43.26%
|
0.76
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
0.02
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
—
|
-0.49
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
-0.08
|
| Unrealized Gain Loss On Investment Securities |
|
-0.22
+14.20%
|
-0.25
+48.56%
|
-0.49
-421.52%
|
-0.09
|
| Change In Working Capital |
|
1.23
+57764.01%
|
-0.00
-102.24%
|
0.10
+201.16%
|
-0.09
|
| Change In Prepaid Assets |
|
-0.09
+66.61%
|
-0.28
-769.73%
|
0.04
-66.37%
|
0.12
|
| Change In Payables And Accrued Expense |
|
1.33
+380.20%
|
0.28
+411.75%
|
0.05
+124.76%
|
-0.22
|
| Change In Accrued Expense |
|
—
|
—
|
—
|
—
|
| Change In Payable |
|
1.33
+380.20%
|
0.28
+411.75%
|
0.05
+124.76%
|
-0.22
|
| Change In Account Payable |
|
1.33
+380.20%
|
0.28
+411.75%
|
0.05
+124.76%
|
-0.22
|
| Investing Cash Flow |
|
-4.28
-126.54%
|
-1.89
-186.29%
|
2.19
+121.56%
|
-10.15
|
| Cash Flow From Continuing Investing Activities |
|
-4.28
-126.54%
|
-1.89
-186.29%
|
2.19
+121.56%
|
-10.15
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.25
|
| Net Investment Purchase And Sale |
|
-4.28
-126.54%
|
-1.89
-186.29%
|
2.19
+122.11%
|
-9.90
|
| Purchase Of Investment |
|
-12.26
+28.92%
|
-17.25
+4.62%
|
-18.09
-82.75%
|
-9.90
|
| Sale Of Investment |
|
7.99
-48.03%
|
15.37
-24.23%
|
20.28
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-0.25
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
+100.00%
|
-0.25
|
| Financing Cash Flow |
|
18.01
+64.25%
|
10.97
+110.24%
|
5.22
-62.76%
|
14.01
|
| Cash Flow From Continuing Financing Activities |
|
18.01
+64.25%
|
10.97
+110.24%
|
5.22
-62.76%
|
14.01
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.31
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.31
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.31
|
| Net Short Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-0.31
|
| Net Other Financing Charges |
|
18.01
+64.25%
|
10.97
+110.24%
|
5.22
-63.57%
|
14.32
|
| Changes In Cash |
|
0.20
-84.01%
|
1.22
+366.01%
|
-0.46
+90.06%
|
-4.62
|
| Effect Of Exchange Rate Changes |
|
-0.00
|
0.00
|
—
|
—
|
| Beginning Cash Position |
|
3.62
+50.90%
|
2.40
-16.06%
|
2.86
-61.77%
|
7.48
|
| End Cash Position |
|
3.82
+5.37%
|
3.62
+50.90%
|
2.40
-16.06%
|
2.86
|
| Free Cash Flow |
|
-13.54
-72.34%
|
-7.86
+0.09%
|
-7.86
+9.92%
|
-8.73
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
0.00
|
| Change In Interest Payable |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-31 View
- 10-K2026-03-26 View
- 8-K2026-03-26 View
- 8-K2026-03-11 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 8-K2026-01-20 View
- 42025-12-03 View
- 8-K2025-11-17 View
- 8-K2025-11-12 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 8-K2025-10-21 View
- 42025-10-15 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|